Mural Oncology (NASDAQ:MURA) Lowered to “Equal Weight” Rating by Morgan Stanley

Morgan Stanley cut shares of Mural Oncology (NASDAQ:MURA) from an overweight rating to an equal weight rating in a research note issued to investors on Tuesday, MarketBeat reports.

Several other analysts also recently issued reports on MURA. Jones Trading restated a “hold” rating on shares of Mural Oncology in a report on Tuesday. Raymond James cut Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 target price on the stock. in a research note on Tuesday. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Mural Oncology in a research report on Wednesday, March 12th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $13.00.

Mural Oncology Trading Up 1.5 %

MURA opened at $1.35 on Tuesday. Mural Oncology has a twelve month low of $1.28 and a twelve month high of $5.12. The stock has a market cap of $23.26 million, a PE ratio of -0.15 and a beta of 3.66. The business’s 50 day moving average is $3.77 and its 200-day moving average is $3.58.

Mural Oncology (NASDAQ:MURA) last released its earnings results on Tuesday, March 11th. The company reported ($2.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same period in the previous year, the business posted ($3.57) earnings per share. As a group, analysts forecast that Mural Oncology will post -7.54 EPS for the current year.

Institutional Investors Weigh In On Mural Oncology

Several large investors have recently made changes to their positions in the company. Commerce Bank bought a new position in shares of Mural Oncology during the 3rd quarter valued at $39,000. FMR LLC raised its holdings in Mural Oncology by 124.7% during the third quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after buying an additional 11,423 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Mural Oncology in the fourth quarter worth about $68,000. Two Sigma Advisers LP bought a new stake in shares of Mural Oncology during the 4th quarter worth about $84,000. Finally, Bridgeway Capital Management LLC acquired a new position in shares of Mural Oncology during the 4th quarter valued at about $94,000. Institutional investors own 80.21% of the company’s stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.